More detail on the FDA’s newly announced COVID-19

New Post Public Reply Private Reply Replies (0) Message Board
Mo Mo #64431
734
More detail on the FDA’s newly announced COVID-19 Guidelines. As noted in the previous post IPIX has 3 separate MTA agreements that could lead to Brilacidin being rapidly approved.
=================
May 13, 2020 06:38 AM EDT
FDA issues two guidances to accelerate Covid-19 treatments:

Michael Mezher

The FDA on Monday evening issued two guidances intended to accelerate the development of products to treat or prevent coronavirus disease (Covid-19), laying out recommendations to help companies get to the investigational new drug application (IND) stage and clinical trial design considerations for later-stage studies.

"Accelerating the investigation of safe and effective therapies that could benefit people affected by the COVID-19 pandemic is one of the FDA’s highest priorities. We are committed to maximizing our regulatory flexibility and using every tool at our disposal to speed the development and availability of these medical products and believe these new guidances will help innovators and researchers do just that,” said FDA Commissioner Stephen Hahn.

The new guidance follows the launch of FDA’s coronavirus treatment acceleration program (CTAP) in March and the National Institutes of Health’s (NIH) Accelerating Covid-19 Therapeutic Innovations and Vaccines (ACTIV) public-private partnership in April. As of Monday, FDA said there are 144 active clinical trials of therapeutics for Covid-19 and that it is aware of more than 450 development programs that are still in planning stages.

Pre-IND guidance

The first of the two guidances focuses on walking drugmakers through the pre-IND process to provide them with feedback and help them get their products into clinical trials in a quick and efficient manner. “To facilitate this, we are urging sponsors to submit a pre-IND meeting request that allows early and thorough review and discussion between the sponsor and FDA, which can lead to more rapid review of subsequent IND and assurance of subject safety,” FDA writes, noting it has assembled a multispecialty, multidisciplinary team within the Center for Drug Evaluation and Research for reviewing drug development proposals for Covid-19.

FDA explains that during the Covid-19 public health emergency, it is consolidating its pre-IND meeting request and package development process “into a single step.”

In most cases, FDA says it will review and respond to pre-IND meeting requests in writing only and that requests will be prioritized based on “completeness of the submission and scientific merit.”

FDA also says that sponsors with active INDs for drugs currently in development or those that have submitted pre-IND meeting requests or INDs to FDA to repurpose an already-approved drug for Covid-19 should submit a new pre-IND meeting request cross-referencing any existing applications for the product instead of amending an existing submission.

Additionally, FDA explains that sponsors should begin discussions about investigational products for Covid-19 through pre-IND meeting requests as opposed to pre-emergency use authorization (pre-EUA) requests. “While we are encouraged to see the rapid development of potential therapies for COVID-19, in most cases the effectiveness of novel or repurposed therapies is unknown at the pre-IND stage. Authorization of drugs through the EUA mechanism involves an understanding that the known and potential benefits outweigh the known and potential risks of the drug for the diagnosis, treatment, or prevention of an appropriate disease or condition. In general, drugs being studied for treatment or prevention of COVID-19 have insufficient data for FDA to make such a determination,” FDA writes.

The guidance goes on to provide specific recommendations for the content of pre-IND meeting request submissions; nonclinical, clinical and quality considerations; and additional recommendations for antiviral and inhalation drugs.

Clinical development

In the second guidance, FDA provides recommendations for clinical trial design for Phase 2 and 3 clinical trials intended to establish safety and efficacy for therapeutic or prophylactic drugs and biologics for Covid-19.


FDA says the guidance is focused on the development of direct antiviral drugs or products with immunomodulatory activity and notes that the guidance does not apply to preventative vaccines or convalescent plasma.

“FDA anticipates this guidance will help sponsors to efficiently design studies that may lead to the review and potential approval of safe and effective drugs and biological products to address the COVID-19 pandemic,” FDA writes.

Specifically, the guidance provides recommendations for study population, trial design, efficacy endpoints, safety and statistical considerations.

FDA says it “strongly recommends that drugs to treat or prevent COVID-19 be evaluated in randomized, placebo-controlled, double-blind clinical trials using a superiority design,” and that standard of care should be applied in all treatment arms.

“Sponsors should address anticipated off-label use of any other drugs, devices, or interventions that might be used to manage COVID-19,” FDA writes.

FDA opens the door to decentralized or platform clinical trials and requests that sponsors considering such studies contact the agency.

FDA also provides a list of what it considers to be important clinical outcome measures for treatment trials, including all-cause mortality, respiratory failure, need for invasive mechanical ventilation and sustained clinical recovery. For prevention trials, FDA says the primary endpoint should be the occurrence of laboratory-confirmed SARS-CoV-2 infection or SARS-CoV-2 infection with symptoms within a prespecified timeframe.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 53

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 141

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 144

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 163

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 82

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
TIER IV Simplifies Autonomous Driving with CARLA 1.0

Updated Category News Views 38

No More Detours in Autonomous Development Ever messed with a puzzle that just won't fit until suddenly, it clicks? That's what TIER IV just pulled off with their latest work on CARLA 1.0, the open-source simulator. There's no more mucking about with that separate Python-based bridge to get things communicating—now we're talking native Autoware support. A direct line to...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 91

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionary Prostate Treatment Program Launches in Dallas

Updated Category News Views 191

Transforming Prostate Care with the TULSA Program The landscape of prostate treatment is evolving, thanks to the groundbreaking advancements brought forth by Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) and its launch of the TULSA program in collaboration with Texas Prostate and Dallas Medical Center. This pioneering initiative aims to cater to the rising need for...

Continue Reading
Addex Expands Share Capital for Future Financial Flexibility

Updated Category News Views 254

Recent Developments at Addex Therapeutics Ad Hoc Announcement Addex Therapeutics, a clinical-stage biopharmaceutical firm, has made a significant move by issuing 34,300,000 new registered shares. These shares, issued by Addex Pharma S.A, a wholly-owned subsidiary, allow the company to strategically increase its issued share capital to CHF 2,186,544.96. This adjustment...

Continue Reading
Jasper Therapeutics Receives Major Boost from Oppenheimer's $80 Target

Updated Category News Views 130

Oppenheimer Affirms Positive Outlook for Jasper Therapeutics Jasper Therapeutics (NASDAQ:JSPR) has recently captured the attention of investors, particularly following Oppenheimer's announcement of its continued support with an Outperform rating and a notable price target set at $80. The positive sentiment originates from the recent findings of a Phase 1b/2a clinical...

Continue Reading
Taylor Morrison Launches New Resort Community Near Jacksonville

Updated Category News Views 286

Taylor Morrison Launches New Resort Community Near Jacksonville In an exciting development for homebuyers, Taylor Morrison, recognized as one of America’s Most Trusted® Home Builders, has officially broken ground on its first resort lifestyle community in the Jacksonville area. This ambitious project, named Esplanade at St. Marys, spans an impressive 1,250 acres and is...

Continue Reading
Middlefield Canadian Income PCC Report: NAV Insights

Updated Category News Views 123

Understanding Middlefield Canadian Income PCC's Financial Position Middlefield Canadian Income PCC is a notable player in the investment landscape, focusing on generating sustainable income from a diversified portfolio. Understanding its net asset value (NAV) is crucial for investors looking to gauge the company's financial stability and growth potential. Current Net...

Continue Reading